ArticleCancer biology & therapy2016
Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.
Article in Cancer biology & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Liquid Biopsy-Based Biomolecular Alterations for the Diagnosis of Triple-Negative Breast Cancer in Adults: A Scoping Review.Diagnostics (Basel, Switzerland) · 2026Review
- Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case-Control Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.British journal of cancer · 2024Article
- Review
- Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach.Veterinary world · 2022Article
- Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity.Journal of clinical medicine · 2022Article
- The effects and possible mechanism of action of apolipoprotein M on the growth of breast cancer cells.Molecular biology reports · 2022Article
- Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.Biochemical pharmacology · 2022Review
- The evaluation of serum lipid profile and apolipoprotein C-1 in the Iranian patients of Oral Squamous Cell Carcinoma.BioMedicine · 2022Article
- Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications.Frontiers in molecular biosciences · 2022Review
- Expression of apolipoprotein C1 in clear cell renal cell carcinoma: An oncogenic gene and a prognostic marker.The Kaohsiung journal of medical sciences · 2021Article
- Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.Medicina (Kaunas, Lithuania) · 2021Review
- Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.International journal of molecular sciences · 2021Review
- Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.International journal of molecular sciences · 2019Review
- Apolipoproteins and cancer.Cancer medicine · 2019Review
- A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.British journal of cancer · 2019Article
- Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer.Oncology letters · 2019Article
- Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.Molecular bioSystems · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with triple-negative breast cancer (TNBC) have poor prognosis because of the aggressive nature of the tumor, delayed diagnosis and non-specific symptoms in the early stages. Identification of novel specific TNBC serum biomarkers for screening and therapeutic purposes therefore remains an urgent clinical requirement.We obtained serum samples from a total of 380 recruited individuals split into mining and testing sets, with the aim of screening for reliable protein biomarkers from TNBC and non-TNBC (NTNBC) sera. Samples were assessed using mass spectrometry, followed by receiver operating characteristic (ROC), survival and hazard function curve as well as multivariate Cox regression analyses to ascertain the potential of the protein constituents as diagnostic and prognostic biomarkers for TNBC.We identified upregulated apolipoprotein C-I (apoC-I) with a validated positive effect on TNBC tumorigenesis, with confirmation in an independent test set and minimization of systematic bias by pre-analytical parameters. The apoC-I protein had superior diagnostic ability in distinguishing between TNBC and NTNBC cases. Moreover, the protein presented a more robust potential prognostic factor for TNBC than NTNBC. The apoC-I protein identified in this study presents an effective novel diagnostic and prognostic biomarker for TNBC, indicating that measurement of the peak intensity at 7785 Da in serum samples could facilitate improved early detection and estimation of postoperative survival prognosis for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.